European Journal of Clinical Pharmacology

, Volume 68, Issue 2, pp 213–217 | Cite as

Repeated administration of berberine inhibits cytochromes P450 in humans

Short Communication

Abstract

Purpose

Berberine is a plant alkaloid that is widely used to treat gastrointestinal infections, diabetes, hypertension, and hypercholesterolemia. Many studies have reported interactions between berberine-containing products and cytochromes P450 (CYPs), but little is known about whether berberine alters CYP activities in humans, especially after repeated doses.

Methods

A two-phase randomized-crossover clinical study in healthy male subjects was performed. After 2 weeks of berberine (300 mg, t.i.d., p.o.) administration, midazolam, omeprazole, dextromethorphan, losartan, and caffeine were used to evaluate enzyme activities of CYP3A4, 2C19, 2D6, 2C9, and CYP1A2, respectively.

Results

A decrease in CYP2D6 activity was observed as the 0–8 h urinary dextromethorphan/dextrorphan increased ninefold (P < 0.01). In addition, losartan/E-3174 ratio doubled (P < 0.01) after BBR administration, indicating a decrease in CYP2C9 activity. CYP3A4 activity was also inhibited, as the Cmax, AUC0–∞, and AUC0–12 of midazolam were increased 38% (P < 0.05), 40% (P < 0.01), and 37% (P < 0.05) after BBR treatment, respectively. Compared with the placebo period, the Tmax and T1/2 of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1′-hydroxymidazolam increased 59% (P < 0.01). There were no statistically significant differences in the pharmacokinetic parameters of the other probe drugs between placebo and the BBR-treated group.

Conclusions

Repeated administration of berberine (300 mg, t.i.d., p.o.) decreased CYP2D6, 2C9, and CYP3A4 activities. Drug-drug interactions should be considered when berberine is administered.

Keywords

Berberine CYP2D6 CYP2C9 CYP3A4 Humans 

Notes

Acknowledgments

We would like to thank all members of Dr. Klaassen’s laboratory for reviewing this short communication. This work was supported by the following grants: National Institute of Health (ES-009649, ES-019487, DK-081461, and RR021940); National Scientific Foundation of China (No. 30801421); Hunan Provincial Innovation Foundation For Postgraduates (No. 2009bsxt020); Huge Project to Boost Chinese Drug Development (No. 2009ZX09501-032); 863 Projects (No. 2009AA022710, 2009AA022703, 2009AA022704)

Conflict of interest

The authors report no conflict of interest.

Reference

  1. 1.
    Vuddanda PR, Chakraborty S, Singh S (2010) Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opin Investig Drugs 19(10):1297–1307. doi: 10.1517/13543784.2010.517745 PubMedCrossRefGoogle Scholar
  2. 2.
    Barnes PM, Bloom B, Nahin RL (2008) Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 12:1–23PubMedGoogle Scholar
  3. 3.
    Wu X, Li Q, Xin H, Yu A, Zhong M (2005) Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol 61(8):567–572. doi: 10.1007/s00228-005-0952-3 PubMedCrossRefGoogle Scholar
  4. 4.
    Etheridge AS, Black SR, Patel PR, So J, Mathews JM (2007) An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 73(8):731–741. doi: 10.1055/s-2007-981550 PubMedCrossRefGoogle Scholar
  5. 5.
    Gunes A, Ozbey G, Vural EH, Uluoglu C, Scordo MG, Zengil H, Dahl ML (2009) Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogn 10(5):769–778. doi: 10.2217/pgs.09.22 CrossRefGoogle Scholar
  6. 6.
    Ryu JY, Song IS, Sunwoo YE, Shon JH, Liu KH, Cha IJ, Shin JG (2007) Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol Ther 82(5):531–540. doi: 10.1038/sj.clpt.6100187 PubMedCrossRefGoogle Scholar
  7. 7.
    Chen XP, Tan ZR, Huang SL, Huang Z, Ou-Yang DS, Zhou HH (2003) Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clin Pharmacol Ther 73(3):264–271. doi: 10.1067/mcp.2003.14 PubMedCrossRefGoogle Scholar
  8. 8.
    Zheng J, Chen B, Jiang B, Zeng L, Tang ZR, Fan L, Zhou HH (2010) The effects of puerarin on CYP2D6 and CYP1A2 activities in vivo. Arch Pharm Res 33(2):243–246. doi: 10.1007/s12272-010-0209-2 PubMedCrossRefGoogle Scholar
  9. 9.
    Li Z, Wang G, Wang LS, Zhang W, Tan ZR, Fan L, Chen BL, Li Q, Liu J, Tu JH, Hu DL, Liu ZQ, Zhou HH (2009) Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects. Xenobiotica 39(10):788–793. doi: 10.1080/00498250903134435 PubMedCrossRefGoogle Scholar
  10. 10.
    Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, Li T, Liu J, Yang TL, Wang D, Zhong XY, Zhou HH (2004) St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 75(3):191–197. doi: 10.1016/j.clpt.2003.09.014 PubMedCrossRefGoogle Scholar
  11. 11.
    Chen Y, Xiao P, Ou-Yang DS, Fan L, Guo D, Wang YN, Han Y, Tu JH, Zhou G, Huang YF, Zhou HH (2009) Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers. Clin Exp Pharmacol Physiol 36(8):828–833. doi: 10.1111/j.1440-1681.2009.05158.x PubMedCrossRefGoogle Scholar
  12. 12.
    Tu JH, He YJ, Chen Y, Fan L, Zhang W, Tan ZR, Huang YF, Guo D, Hu DL, Wang D, Hong-Hao Z (2010) Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol 66(8):805–810. doi: 10.1007/s00228-010-0814-5 PubMedCrossRefGoogle Scholar
  13. 13.
    Ghassabian S, Chetty M, Tattam BN, Chem MC, Glen J, Rahme J, Stankovic Z, Ramzan I, Murray M, McLachlan AJ (2009) A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients. Ther Drug Monit 31(2):239–246. doi: 10.1097/FTD.0b013e318197e1bf PubMedCrossRefGoogle Scholar
  14. 14.
    Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F, Eliasson E, Dahl ML (2002) Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71(1):89–98. doi: 10.1067/mcp.2002.121216 PubMedCrossRefGoogle Scholar
  15. 15.
    Alfaro CL, Lam YW, Simpson J, Ereshefsky L (1999) CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol 19(2):155–163PubMedCrossRefGoogle Scholar
  16. 16.
    Yang LH, Lu FE, Dong H, Xu LJ, Wang KF (2005) Effect of emodin and berberine on gastrointestinal motility in type 2 diabetic rats. World Chin J Digestol 13(5):608–611Google Scholar
  17. 17.
    Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H, Lesko LJ (2008) New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48(6):662–670. doi: 10.1177/0091270007312153 PubMedCrossRefGoogle Scholar
  18. 18.
    Guo Y, Li F, Ma XC, Cheng XG, Zhou HH, Klaassen CD (2011) CYP2D plays a major role in berberine metabolism in liver of mice and humans. Xenobiotica. doi: 10.3109/00498254.2011.597456

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Pharmacogenetics Research Institute, Institute of Clinical PharmacologyCentral South University, XiangYa School of MedicineChangshaPeople’s Republic of China
  2. 2.Department of Pharmacology, Toxicology and TherapeuticsUniversity of Kansas Medical CenterKansas CityUSA

Personalised recommendations